T. Rowe Price Associates’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $288K | Hold |
79,910
| – | – | ﹤0.01% | 2548 |
|
|
2025
Q1 | $239K | Buy |
79,910
+6,027
| +8% | +$18K | ﹤0.01% | 2557 |
|
|
2024
Q4 | $248K | Buy |
73,883
+3,882
| +6% | +$13K | ﹤0.01% | 2587 |
|
|
2024
Q3 | $235K | Buy |
70,001
+3,341
| +5% | +$11.2K | ﹤0.01% | 2588 |
|
|
2024
Q2 | $221K | Sell |
66,660
-477
| -0.7% | -$1.58K | ﹤0.01% | 2555 |
|
|
2024
Q1 | $272K | Buy |
67,137
+11,968
| +22% | +$48.5K | ﹤0.01% | 2476 |
|
|
2023
Q4 | $169K | Buy |
55,169
+12,927
| +31% | +$39.6K | ﹤0.01% | 2597 |
|
|
2023
Q3 | $127K | Buy |
42,242
+1,010
| +2% | +$3.04K | ﹤0.01% | 2613 |
|
|
2023
Q2 | $155K | Buy |
41,232
+1,488
| +4% | +$5.59K | ﹤0.01% | 2591 |
|
|
2023
Q1 | $134K | Buy |
39,744
+10,931
| +38% | +$36.9K | ﹤0.01% | 2623 |
|
|
2022
Q4 | $139K | Buy |
28,813
+1,192
| +4% | +$5.75K | ﹤0.01% | 2640 |
|
|
2022
Q3 | $158K | Buy |
27,621
+4,540
| +20% | +$26K | ﹤0.01% | 2613 |
|
|
2022
Q2 | $164K | Sell |
23,081
-422,879
| -95% | -$3M | ﹤0.01% | 2642 |
|
|
2022
Q1 | $3.22M | Buy |
445,960
+33,045
| +8% | +$239K | ﹤0.01% | 1553 |
|
|
2021
Q4 | $3.69M | Sell |
412,915
-1,083,050
| -72% | -$9.68M | ﹤0.01% | 1543 |
|
|
2021
Q3 | $52.4M | Sell |
1,495,965
-195,517
| -12% | -$6.85M | ﹤0.01% | 989 |
|
|
2021
Q2 | $36.3M | Sell |
1,691,482
-869,893
| -34% | -$18.7M | ﹤0.01% | 1137 |
|
|
2021
Q1 | $154M | Buy |
2,561,375
+43,398
| +2% | +$2.61M | 0.02% | 633 |
|
|
2020
Q4 | $102M | Buy |
+2,517,977
| New | +$102M | 0.01% | 720 |
|